SG Americas Securities
RNAC icon

SG Americas Securities’s Cartesian Therapeutics RNAC Stock Holding History

SG Americas Securities’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,571
Closed -$31K – 3248
2024
Q1 		$31K Sell
1,571
-1,799
-53% -$38.1K ﹤0.01% 2832
2023
Q4 		$70K Buy
3,370
+1,972
+141% +$58.9K ﹤0.01% 2860
2023
Q3 		$44K Buy
+1,398
New +$46.7K ﹤0.01% 2967
2022
Q3 		– Sell
-385
Closed -$15K – 3496
2022
Q2 		$15K Sell
385
-1,861
-83% -$55.2K ﹤0.01% 3353
2022
Q1 		$83K Buy
2,246
+1,041
+86% +$65.1K ﹤0.01% 2790
2021
Q4 		$118K Sell
1,205
-13,130
-92% -$1.41M ﹤0.01% 2985
2021
Q3 		$1.79M Sell
14,335
-16,933
-54% -$2.04M 0.01% 1379
2021
Q2 		$3.92M Buy
31,268
+22,985
+277% +$2.74M 0.02% 719
2021
Q1 		$1.12M Buy
8,283
+7,754
+1,466% +$963K 0.01% 1452
2020
Q4 		$48K Buy
+529
New +$45.9K ﹤0.01% 3147
2020
Q3 		– Sell
-743
Closed -$63K – 3336
2020
Q2 		$63K Buy
+743
New +$67.4K ﹤0.01% 3496
2018
Q1 		– Sell
-493
Closed -$145K – 3501
2017
Q4 		$145K Buy
+493
New +$215K ﹤0.01% 2652

Other funds holding RNAC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

SG Americas Securities's RNAC Position: Q2 2024 in Review

SG Americas Securities sold out of Cartesian Therapeutics (RNAC) in Q2 2024, closing a stake of 1,571 shares — an estimated $31K sold.

SG Americas Securities first reported a position in RNAC in Q4 2017 and held it in 12 quarters. The position peaked at $3.92M in Q2 2021. 61 funds tracked by Wall St. Rank hold RNAC as of Q2 2024.

  • SG Americas Securities reported no remaining Cartesian Therapeutics position as of Q2 2024 after selling out during the quarter.
  • SG Americas Securities sold 1,571 Cartesian Therapeutics shares in Q2 2024, an estimated $31K.
  • SG Americas Securities first reported a position in Cartesian Therapeutics in Q4 2017 and held it in 12 quarters.
  • SG Americas Securities's Cartesian Therapeutics position peaked at $3.92M in Q2 2021.
  • 61 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2024.

Based on SG Americas Securities's 13F filing for Q2 2024, filed 12 Jul 2024.